Comparative Pharmacology
Head-to-head clinical analysis: RENO 30 versus RENOGRAFIN 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENO 30 versus RENOGRAFIN 60.
RENO-30 vs RENOGRAFIN-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
RENOGRAFIN-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality, iodinated contrast agent. It enhances radiographic contrast by absorbing X-rays due to the high atomic number of iodine. It distributes into the intravascular space and is excreted primarily by the kidneys via glomerular filtration without significant tubular reabsorption or secretion.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
Intravenous: 50-100 mL of a 60% solution as a single dose for CT or angiography. Intra-arterial: 5-50 mL depending on vessel size. Maximum total dose: 3 mL/kg.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 1-2 hours in normal renal function. Prolonged in renal impairment: up to 50 hours. Clinically significant for timing of contrast imaging and risk of contrast-induced nephropathy.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: 95-100% (glomerular filtration, no tubular reabsorption). Biliary/Fecal: negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent